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utotaxin (ATX) is a tumor cell motility–stimulating
factor, originally isolated from melanoma cell super-
natants. ATX had been proposed to mediate its effects
through 5
 
 
 
-nucleotide pyrophosphatase and phosphodi-
 
esterase activities. However, the ATX substrate mediat-
ing the increase in cellular motility remains to be identi-
ﬁed. Here, we demonstrated that lysophospholipase D
(lysoPLD) puriﬁed from fetal bovine serum, which catalyzes
the production of the bioactive phospholipid mediator,
lysophosphatidic acid (LPA), from lysophosphatidylcholine
(LPC), is identical to ATX. The Km value of ATX for LPC was
 
25-fold lower than that for the synthetic nucleoside substrate,
 
p
 
-nitrophenyl-tri-monophosphate. LPA mediates multiple
A
 
biological functions including cytoskeletal reorganization,
chemotaxis, and cell growth through activation of speciﬁc
G protein–coupled receptors. Recombinant ATX, particularly
in the presence of LPC, dramatically increased chemotaxis
and proliferation of multiple different cell lines. Moreover,
we demonstrate that several cancer cell lines release signiﬁ-
cant amounts of LPC, a substrate for ATX, into the culture
medium. The demonstration that ATX and lysoPLD are
identical suggests that autocrine or paracrine production of
LPA contributes to tumor cell motility, survival, and prolifer-
ation. It also provides potential novel targets for therapy of
pathophysiological states including cancer.
 
Introduction
 
Lysophosphatidic acid (1- or 2-acyl-lysophosphatidic
acid; LPA)* is an autacoid-like lipid mediator with multiple
biological functions including induction of platelet ag-
 
gregation, smooth muscle contraction, and stimulation
of cell proliferation and chemotaxis (Moolenaar, 1999;
Contos et al., 2000). LPA evokes its multiple effects
through G protein–coupled receptors, with subsequent
activation of PLC and phospholipase D, Ca
 
2
 
 
 
 mobilization,
inhibition of adenylyl cyclase, activation of MAPK, and
transcription of serum response element–regulated genes,
such as c
 
-fos
 
. LPA mediates its activity through a series of
G protein–coupled receptors of the endothelial differentiation
gene (EDG) family (Hecht et al., 1996; An et al., 1998;
Bandoh et al., 1999).
In contrast to the extensive analysis of mechanisms under-
lying LPA signaling mediated by the LPA receptor family,
the enzymes regulating LPA production and degradation
have not been characterized fully. LPA can be produced
by a variety of cells including platelets, fibroblasts, adipocytes,
and ovarian cancer cells (Gerrard and Robinson, 1989;
Eichholtz et al., 1993; Shen et al., 1998). LPA is also pro-
duced by the action of extracellular lysophospholipase D
(lysoPLD) on lysophosphatidylcholine (LPC; Tokumura
 
Address correspondence to Junken Aoki, Graduate School of Pharmaceu-
tical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku,
Tokyo 113-0033 Japan. Tel.: 81-3-5841-4723. Fax: 81-3-3818-3173.
E-mail: jaoki@mol.f.u-tokyo.ac.jp
M. Umezu-Goto and Y. Kishi contributed equally to this paper.
K. Inoue’s present address is Faculty of Pharmaceutical Sciences, Teikyo
University, Sagamiko, Tsukui, Kanagawa 199-0195, Japan.
*Abbreviations used in this paper: ATX, autotaxin; EDG, endothelial
 
differentiation gene; LPA, lysophosphatidic acid; LPC, lysophosphatidyl-
 
choline; lysoPLD, lysophospholipase D; pNP-TMP, 
 
p
 
-nitrophenyl-
tri-monophosphate.
Key words: lysoPLD; EDG receptor; lysophosphatidylcholine; chemotaxis;
cell proliferation 
228 The Journal of Cell Biology 
 
|
 
 
 
Volume 158, Number 2, 2002
 
et al., 1986), which is present at high micromolar levels in
plasma (Okita et al., 1997; Tokumura et al., 1999; Croset
et al., 2000). LPA can be detected in various biological flu-
ids such as serum, plasma, ascites, and saliva (Tokumura et
al., 1986, 1999; Tigyi and Miledi, 1992), and its levels are
elevated in diverse physiological and pathological condi-
tions such as pregnancy, high cholesterol diet, and ovarian
cancer (Xu et al., 1995; Tokumura et al., 2000, 2002).
Plasma lysoPLD appears to mediate the production of LPA
in plasma (Tokumura et al., 1986), potentially contribut-
ing to the aberrant LPA levels in pathophysiological states.
To characterize the as yet uncloned lysoPLD and to further
elucidate the biological function of LPA, we purified
lysoPLD from biological fluids.
 
Results and discussion
 
Purification and identification of lysoPLD as autotaxin
 
As assessed by the ability to liberate choline from LPC,
lysoPLD activities are widely distributed in various biological
fluids including serum and cerebrospinal fluid, with the high-
est activity being present in FBS. Thus, we purified lysoPLD
from FBS (Fig. 1, A–C), resulting in an 
 
 
 
10,000-fold in-
crease in specific activity. In each chromatographic step,
lysoPLD activity eluted as a single peak (unpublished data),
suggesting the presence of a single lysoPLD enzyme in FBS.
Gel filtration and Con A column chromatography demon-
strated that lysoPLD is a glycoprotein with an apparent mo-
lecular mass of 100 kD (unpublished data). Matrix-assisted
laser desorption ionization mass spectrometry and Edman
Figure 1. Purification of lysoPLD and identification as ATX. (A) Strategy used for purification of lysoPLD. (B) Elution profile of lysoPLD activity 
on hydroxylapatite column chromatography (CHT-II). The flow-through fractions of the RESOURCE
® PHE hydrophobic column were applied 
to a CHT-II column, and the absorbed proteins were eluted with a linearly increasing gradient of KH2PO4 (0–0.4 M). 1.5 ml-fractions were 
collected, examined for lysoPLD activity (closed circle), and protein concentration was monitored by absorbance at 280 nm (dashed line). 
(C) The active fractions from the CHT-II column were subjected to SDS-PAGE and the proteins were detected by silver staining. Arrows indicate 
the protein bands that co-migrate with lysoPLD activity. The lower band ( 30 kD) was a degradation product of the 100-kD band as judged 
by mass spectrometry and sequence analyses (unpublished data). In the bottom panel, an enlarged picture of the active fractions (fractions 
42–52) is shown. The 100-kD band is indicated by an asterisk. (D) Alignment of peptide sequences obtained from amino acid sequence analysis 
of bovine lysoPLD with the amino acid sequence of rat autotaxin. Numbers in the second lines correspond to the amino acid numbers of rat 
ATX. Identical amino acids were indicated by colons. (E) Expression of ATX/lysoPLD recombinant protein in CHO-K1 cells. Culture supernatant 
or cells from myc epitope–tagged ATX/lysoPLD-pcDNA3 or control pcDNA3 vector transfected CHO-K1 were subjected to Western blot analysis 
using anti-myc mAb (9E11). ATX/lysoPLD protein was recovered almost exclusively from culture supernatant of ATX/lysoPLD-pcDNA3–
transfected cells. (F) Recombinant ATX shows lysoPLD activity as assessed by choline release. The culture supernatant of ATX/lysoPLD-pcDNA3 
(closed circle) or control pcDNA3 vector–transfected CHO-K1 (open circle) was subjected to a lysoPLD assay. (G) Formation LPA by lysoPLD. 
Phospholipids in the lysoPLD reaction (F) were analyzed by TLC after the lipids in the reaction mixture were extracted by organic solvents. 
LPC or LPA is included to indicate migration on the TLC plate. 
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degradation of a lysylendopeptidase digest of the 100-kD
protein after hydroxyapatite column chromatography (Fig. 1,
B and C) showed three polypeptide sequences: FNHRW-
WGGQPLWITATK, YASERNGVNVISGPIFDYDYDGL-
HDTEDK, and MHTARVRDIEHLTSLDFFRK. These
three sequences showed high (
 
 
 
95% identity) homology to
rat, murine, and human autotaxin (ATX; Fig. 1 D). ATX is
an autocrine motility factor that stimulates pertussis toxin–
sensitive cell motility in human melanoma cells and possesses
phosphodiesterase and pyrophosphatase activities (Stracke et
al., 1992, 1997; Murata et al., 1994; Clair et al., 1997).
LysoPLD catalyzes the hydrolysis of LPC phosphodiester
bonds, which is compatible with it belonging to the same
phosphodiesterase family as ATX.
ATX, a type II transmembrane ectoenzyme with multiple
domains, is released from the cell by cleavage of the 12th
amino acid external to the transmembrane domain (Stracke
et al., 1997). Recombinant ATX was detected almost exclu-
sively in culture supernatants of transfected CHO-K1 cells
(Fig. 1 E) indicative of efficient extracellular cleavage. Simi-
larly, lysoPLD activity, as assessed by choline production
from LPC, was detected at high levels in the supernatants of
ATX cDNA–transfected CHO-K1 cells but not in vector-
transfected cells (Fig. 1 F), which is compatible with ATX
possessing lysoPLD activity. Consistent with ATX possess-
ing lysoPLD activity, LPA was readily detected by TLC after
the addition of recombinant ATX to LPC (Fig. 1 G). ATX
has been previously demonstrated to exhibit phosphodi-
esterase activity toward various nucleotide substrates includ-
ing nucleotide triphosphate (NTP), nucleotide diphosphate
(NDP), and a synthetic substrate, 
 
p
 
-nitrophenyl-tri-mono-
phosphate (pNP-TMP; Clair et al., 1997). The V
 
max
 
 and K
 
m
 
values of recombinant ATX calculated from Lineweaver-
Burk plots are 9.0 nmol/min
 
  
 
g and 250 
 
 
 
M for LPC, and
11.0 nmol/min
 
  
 
g and 14.1 mM for pNP-TMP, indicating
a much higher affinity of ATX for LPC than that for pNP-
TMP. Similar results were obtained when lysoPLD purified
from FBS was assessed. Combined with the observation that
LPC is present at high micromolar levels in biological fluids
(Tokumura et al., 1999; Croset et al., 2000), LPC is likely to
serve as a physiologically relevant substrate for ATX. Both
purified lysoPLD and recombinant ATX failed to hydrolyze
phosphatidylcholine with two long acyl chains, indicating
that lysoPLD is selective for the lyso form of phospholipids
(unpublished data).
 
ATX/lysoPLD stimulates cell motility particularly in the 
presence of LPC
 
The cell motility–stimulating activity of ATX on tumor cells
requires an intact catalytic domain (Lee et al., 1996), how-
ever, the ATX substrate essential for the ability of ATX to
induce cell motility has yet to be identified. In the following
experiments, we investigated whether the cell motility–stim-
ulating activity of ATX (Stracke et al., 1992; Fig. 2 A) could
be explained by its lysoPLD activity because of the observa-
tion that LPA, the product of lysoPLD, is an effective in-
ducer of chemotaxis in multiple cell lineages (Imamura et
al., 1993; Stam et al., 1998; Sturm et al., 1999; Manning et
al., 2000). Consistent with previous observations (Stracke
et al., 1992), recombinant ATX produced in Sf9 cells stimu-
lated a dose-dependent chemotaxis of the human melanoma
A-2058 cell line using a Boyden chamber assay (Fig. 2 A).
Interestingly, the ability of recombinant ATX to induce mo-
tility was dramatically increased by the addition of LPC, a
substrate for lysoPLD (Fig. 2 A). LPC alone was insufficient
to alter cell motility (Fig. 2 A). The addition of nucleotide
substrates of ATX, including ATP, ADP, and adenosine (up
to 100 
 
 
 
M) failed to alter the effects of ATX on cell motility
(unpublished data). In contrast, exogenous LPA was suffi-
cient to stimulate motility of A-2058 melanoma cells (Fig. 2
B). ATX in the absence of exogenous LPC was sufficient to
modestly increase cellular motility (Fig. 2 A). If the effects of
ATX on cellular motility are due to the hydrolysis of LPC
and the subsequent action of LPA on cells, LPC must be
present in the cells or cell supernatants. One possible expla-
nation is that cancer cells can release LPC into culture me-
dia, which may in turn serve as substrate for ATX, resulting
in the production of LPA which, in turn, induces cellular
motility (see Fig. 4 A and next paragraph).
 
ATX/lysoPLD stimulates cell proliferation of multiple 
cancer cell lines
 
LPA has been demonstrated to be a potent inducer of cell
proliferation (van Corven et al., 1989, 1992), an activity
that had not previously been attributed to ATX. If ATX me-
diates LPA production from LPC, ATX could manifest pro-
liferation-stimulating activity, particularly in the presence of
exogenous LPC. As shown in Fig. 3 A, recombinant ATX
stimulated proliferation of multiple cell lines including
A-2058 melanoma cells, the breast cancer cell line MDA-
MB-231, and CHO-K1 cells. As expected, LPA also stimulated
Figure 2. ATX/lysoPLD-induced 
chemotaxis is enhanced by lysophos-
phatidylcholine in A-2058 melanoma 
cells. (A) Lysophosphatidylcholine (LPC) 
enhances chemotaxis of A-2058 cells 
induced by recombinant ATX/lysoPLD. 
ATX/lysoPLD-induced chemotaxis was 
assessed in the presence or absence of 
LPC (1-oleoyl, 1  M; closed triangle) or 
10  M (closed circle; mean   SEM, 
n   4). ATX/lysoPLD was produced by 
baculovirus (see Materials and methods). 
(B) Dose dependency of LPA (1-oleoyl)-
induced chemotaxis of A-2058 and 
CHO-K1 cells (mean   SEM, n   4; see 
Materials and methods). 
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the proliferation of these cells (Fig. 3 B). The proliferation-
stimulating activity of ATX was, once again, markedly in-
creased by the addition of LPC to the media (Fig. 3 A). To
further ascertain whether the activity of ATX can be attrib-
uted to its ability to produce LPA, we determined whether
the ability of recombinant ATX to induce cellular prolifera-
tion required the expression of functional LPA receptors.
RH7777 cells, which show no or little expression of func-
tional LPA receptors (Fukushima et al., 1998), were mini-
mally stimulated by LPA, whereas stable expression of the
EDG2/LPA1 LPA receptor rendered RH7777 responsive to
LPA-induced cellular proliferation (Fig. 3 B). Similarly, re-
combinant ATX exhibited minimal (if any) effect on the
proliferation of parental RH7777 cells. Once again, expres-
sion of EDG2/LPA1 in RH7777 cells rendered the cells re-
sponsive to recombinant ATX, a process that was aug-
mented by exogenous LPC (Fig. 3 A). As noted above, ATX
was sufficient to modestly increase the proliferation of
A-2058, MDA-MB-231, CHO-K1, and EDG2-RH7777
cells, which could be explained if these cell lines produce
LPC. As demonstrated in Fig. 4 A, LPC (which is a substrate
for ATX) could be readily detected in culture media of
A-2058, MDA-MB-231, CHO-K1, and EDG2-RH7777
cells, suggesting that the effects of ATX in the absence of ex-
ogenous LPC could be mediated by the conversion of en-
dogenously produced LPC to LPA.
Exogenous LPC was not sufficient to increase the prolifer-
ation of CHO-K1 or EDG2-RH7777 cells (Fig. 3 A). In
contrast, exogenous LPC did increase the proliferation of
A-2058 and MDA-MB-231 cells (Fig. 3 A). These results co-
incided with the observation that lysoPLD activity was
readily detectable in the supernatant of A-2058 and MDA-
MB-231 cells, but not CHO-K1 or EDG2-RH7777 cells
(Fig. 4 B). As assessed by RT-PCR, A-2058 and MDA-MB-
231 cells, but not CHO-K1 or EDG2-RH7777 cells, ex-
press ATX mRNA (unpublished data). Thus, the conversion
of exogenously added LPC to LPA by endogenously ex-
pressed ATX appears sufficient to result in the proliferation
of A-2058 and MDA-MB-231 cells.
Here, we have demonstrated that lysoPLD is identical to
ATX and provided evidence that LPA, the product of
ATX/lysoPLD, mediates chemotaxis and proliferation of
cancer cells. LPA is known to stimulate both chemotaxis
(Imamura et al., 1993; Stam et al., 1998; Sturm et al.,
1999; Manning et al., 2000) and proliferation (van Corven
et al., 1989, 1992) of multiple cell lineages. The LPA re-
ceptors, in particular the EDG2 receptor analyzed here,
can couple with pertussis toxin–sensitive G
 
i
 
 (Hecht et al.,
1996), which is consistent with the effect of pertussis toxin
on cell motility induced by ATX. As assessed by quantita-
tive PCR, all of the cancer cell lines (with the exception of
RH7777) used here express EDG2 (unpublished data).
Some tumor cells appear to be capable of secreting factors
that stimulate their own motility, survival, and growth. Al-
though autocrine secretion of motility factors might play a
role in the initiation of tumor cell invasion, autocrine se-
cretion of growth factors by tumor cells might contribute
to the proliferation and survival of metastatic colonies.
Both chemoattractant and proliferative activities can be
stimulated by LPA, which can be produced by the action
of ATX/lysoPLD on LPC. LPC is present at high levels in
plasma, providing a potential source for paracrine or endo-
crine action of ATX. In the microenvironment of the tu-
mor, LPC secreted by tumor cells may play an important
role in ATX-mediated autocrine motility and proliferation
of tumor cells.
LPC was detected in the culture media of various cell
types (Fig. 4 A). Indeed, LPC levels in culture supernatants
of RH7777 cells were 
 
 
 
1 
 
 
 
M. The release of LPC (Fig. 4
A) from cells was dependent on the presence of BSA in the
Figure 3. ATX/lysoPLD stimulates cell proliferation. (A) ATX/lysoPLD stimulates cell growth of cancer cell lines and LPA receptor–expressing 
rat hepatoma cells. Cells were starved for 48 h. Cell proliferation induced by the addition of recombinant ATX/lysoPLD both in the 
presence or absence of 10  M LPC (1-oleoyl) was evaluated by MTT hydrolysis (mean   SEM, n   3). The following cells were used: 
A-2058 (melanoma, human), MDA-MB-231 (breast cancer, human), CHO-K1 (ovary-derived fibroblast, hamster), RH7777-EDG2, and 
parental RH7777 (hepatoma, rat). (B) Dose dependency of LPA (1-oleoyl)-induced cell growth. LPA-induced cell growth was assessed by 
MTT hydrolysis as in A (mean   SEM, n   3). 
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media (unpublished data), which is capable of removing
LPC from the outer membrane leaflet. LPC is also present at
significant levels in intact cells (unpublished data). Thus,
LPC released from cells or in the extracellular leaflet of the
cell membrane could be a source of substrate for lysoPLD. A
similar mechanism for LPA production was proposed by van
Dijk et al. (1998) using bacterial phospholipase D. Indeed,
when cell supernatants of RH7777 cells, which release high
levels of LPC, were incubated with lysoPLD, LPA was
readily detectable (unpublished data). ATX/lysoPLD was
also present in the supernatant of a number of cancer cell
lines. Thus, there is the potential for an autocrine loop
where both ATX/lysoPLD and LPC are produced by the
same cells, leading to LPA production. Alternatively, para-
crine loops may occur where cells produce one (but not
both) of ATX/lysoPLD or LPC.
ATX/lysoPLD (also called NPP-2) shares significant ho-
mology (
 
 
 
45% in amino acid level) with members of the
nucleotide pyrophosphatase/phosphodiesterase (NPP) fam-
ily, which includes PC-1/NPP-1 and gp130
 
RB13–6
 
/NPP-3.
PC-1/NPP-1 and gp130
 
RB13–6
 
/NPP-3 have been impli-
cated in multiple processes, including bone mineralization
(Okawa et al., 1998; Nakamura et al., 1999) and signaling
by insulin and by nucleotides (Bollen et al., 2000). As with
ATX/lysoPLD, the biological effects of other NPP family
members require a functional catalytic site. However, the
physiological substrates for these two enzymes still remain to
be identified. Indeed, it is possible that similar to ATX/
lysoPLD, their substrates may be lipidlike molecules and po-
tentially lysophospholipids.
 
Materials and methods
 
Materials
 
LPC (1-oleoyl) and LPA (1-oleoyl) were obtained from Avanti Polar Lipids,
Inc. FBS was purchased from JRH Biosciences, Inc. Other chemicals were
purchased from Sigma-Aldrich.
 
Purification of lysoPLD
 
5–10% polyethleneglycol precipitate of FBS was loaded onto blue
Sepharose 6 Fast Flow (Amersham Biosciences), and eluted with a linear
gradient of NaCl (0–2 M). The active fractions were loaded onto Con A
Sepharose (Amersham Biosciences) and eluted with 5 mM 
 
 
 
-methylman-
nopyranoside at room temperature. The active fractions from the eluate
were sequentially loaded onto a BioAssist Q ion exchange column
 
(TOSOH) and a HiTrap™ heparin column (Amersham Biosciences), and
were eluted with a linear gradient of NaCl (0–0.5 M). Active fractions
were loaded onto a RESOURCE
 
®
 
 PHE hydrophobic column (Amersham
Biosciences). Active fractions (flow-through fractions) were loaded onto
an Econo-Pac CHT-II hydroxyapatite column (Bio-Rad Laboratories), and
eluted with a linear gradient of Na
 
2
 
HPO
 
4
 
 (0–0.15 M). All column chro-
matography was performed at a neutral pH (7.5). The latter four-column
chromatography steps were performed using ÄKTA™ (Amersham Bio-
sciences). Amino acid sequence analysis of purified lysoPLD was per-
formed as described previously (Takeda et al., 2001).
 
LysoPLD assay
 
1–50-
 
 
 
l samples were incubated with 1 mM LPC (from egg) in the
presence of 100 mM Tris-HCl, pH 9.0, 500 mM NaCl, 5 mM MgCl
 
2
 
,
and 0.05% Triton X-100 for 1 h at 37
 
 
 
C. The liberated choline was de-
tected by an enzymatic photometric method using choline oxidase
(Asahi Chemical), horseradish peroxidase (Toyobo), and TOOS reagent
(
 
N
 
-ethyl-
 
N
 
-(2-hydoroxy-3-sulfoproryl)-3-methylaniline; Dojindo Molecular
Technologies, Inc.) as a hydrogen donor (Imamura and Horiuti, 1978;
Tamaoku et al., 1982).
 
Plasmids and recombinant enzyme
 
Rat cDNA for ATX (corresponding to human autotaxin-T) was amplified by
RT-PCR using a rat liver cDNA library as template DNA based on the se-
quence information in the database (
 
Rattus norvegicus
 
 ectonucleotide py-
rophosphatase/phosphodiesterase 2; GenBank/EMBL/DDBS
 
 
 
accession no.
NM_057104). A myc-tag was added at the COOH terminus. Transient
transfection into CHO-K1 cells was performed using LipofectAMINE™ (In-
vitrogen). The rat cDNA for ATX was also introduced into the baculovirus
transfer vector pFASTBac-1 (Invitrogen), and recombinant baculovirus was
prepared according to the manufacturer’s protocol. Purification of recom-
binant ATX/lysoPLD protein was performed as described above from 1 liter
of culture supernatant of Sf9 insect cells infected with ATX/lysoPLD re-
combinant baculovirus.
 
Chemotaxis assay
 
A-2058 cells were maintained in RPMI 1640 with 5% heat-inactivated
FBS at 37
 
 
 
C and 5% CO
 
2
 
. Polycarbonate filters with 8-
 
 
 
m pores (Neuro
Probe, Inc.) were coated with 13.3 mg/ml fibronectin (Sigma-Aldrich) in
PBS for 60 min. A dry coated filter was placed on a 96-blind well cham-
ber (Neuro Probe, Inc.) containing the indicated amounts of LPA (18:1;
Avanti Polar Lipids, Inc.) or ATX/lysoPLD recombinant protein both in
the presence or absence of 1 or 10 
 
 
 
M LPC (1-oleoyl; Avanti Polar Lip-
ids, Inc.), and cells (200 
 
 
 
l, 8 
 
 
 
 10
 
4
 
 per well) were added to the top
wells. The ligand solution and cell suspension were prepared in the same
buffer (serum-free RPMI 1640 medium containing 0.1% BSA). After incu-
bation at 37
 
 
 
C in 5% CO
 
2
 
 for 4 h, the filter was disassembled. The cells
on the filter were fixed with methanol and stained with a Diff-Quick
staining kit (International Reagents Corp.). The top side of the filter was
scraped free of cells. The number of cells that migrated to the bottom
side was determined by measuring optical densities at 595 nm using a
96-well microplate reader (model 3550; Bio-Rad Laboratories). When
LPC or LPA was added to the cells, it was suspended in serum-free media
containing 0.1% BSA.
Figure 4. Secretion of LPC and expression of 
lysoPLD activity by a variety of cell lineages. 
(A) Monolayers of cell lines were preincubated 
with [
32P]orthophosphoric acid for 12 h. Lipids in 
the culture medium were extracted with chloroform 
and methanol, and then subjected to TLC. 
Radioactivity of each lipid spot was detected and 
visualized using an image analyzer. Identification 
of each lipid spot was confirmed by using standard 
lipids both in one- and two-dimensional TLC 
(unpublished data). (B) Cancer cells secrete 
lysoPLD. Cells were cultured for 48 h in serum-free 
medium, and the lysoPLD activity of the culture 
medium was determined (see Materials and 
methods). The following cells were used: A-2058, 
MDA-MB-231, CHO-K1, RH7777-EDG2, and 
parental RH7777. 
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Proliferation assay
 
Human EDG2 cDNA (in pcDNA3 expression vector) was cloned as de-
scribed previously (Bandoh et al., 1999). Rat hepatoma RH7777 cells sta-
bly expressing human LPA1/EDG2 were established as described previ-
ously (Fukushima et al., 1998). Cancer cell lines were obtained from
American Type Culture Collection. MDA-MB-231 cells were maintained
in RPMI 1640 with 5% heat-inactivated FBS at 37
 
 
 
C and 5% CO
 
2
 
. CHO-
K1 and RH7777 cells were maintained in Ham’s F12 and DME, respec-
tively, with 10% heat-inactivated FBS at 37
 
 
 
C and 5% CO
 
2
 
. Cells were
seeded in 96-well plates and cultured for 24 h. Cells were starved for 48 h
by replacing the media with serum-free media (DME for RH7777 cells,
Ham’s F12 for CHO-K1 cells, and RPMI 1640 for other cancer cells) con-
taining 0.1% BSA, followed by addition of the indicated amount of LPA or
recombinant ATX/lysoPLD in the presence or absence of LPC (10 
 
 
 
M). The
cells were further cultured for 48 h. Cell proliferation was evaluated by
MTT hydrolysis using Cell Counting Kit-8 (Dojindo Molecular Technolo-
gies, Inc.). When LPC or LPA was added to the cells, it was suspended in
serum-free media containing 0.1% BSA.
 
Lipid analysis
 
Phospholipids in reaction mixture, cells, or culture media were extracted
by the method of Bligh and Dyer (1959) under acidic conditions by ad-
justing the pH to 3.0 with 1 N HCl to recover LPA efficiently. Lipids in the
aqueous phase were reextracted and pooled with the previous organic
phase. The extracted lipids were dried, dissolved in chloroform/methanol
(1:1), and used for thin TLC analysis using chloroform/methanol/formic
acid/H
 
2
 
O (60:30:7:3, vol/vol) for 1-D TLC, and chloroform/methanol/for-
mic acid/H
 
2
 
O (60:30:7:3, vol/vol) and chloroform/methanol/28% ammo-
nia/H
 
2
 
O (50:40:8:2, vol/vol) for 2-D TLC as organic solvents. Phospholip-
ids were detected using iodine vapor. For detection of LPC in cultured
cells, cells were cultured for 12 h in the presence of [
 
32
 
P]orthophosphate
(50 
 
 
 
Ci/ml) and serum-free media containing 0.1% BSA in 12-well plates
before the lipid extraction. The radioactivities were detected using an im-
age analyzer (model BAS 2000; Fuji Film). The recovery of lipids was
monitored by the addition of trace amounts of 1-[
 
3
 
H]oleoyl–LPC or
1-[
 
3
 
H]oleoyl–LPA to the samples. Under the described conditions, recov-
eries of 1-[
 
3
 
H]oleoyl–LPC and 1-[
 
3
 
H]oleoyl–LPA were always 
 
 
 
95%.
Concentration of LPC was determined by an enzyme-linked fluorometric
method. After the lipids in the samples were extracted and concentrated,
LPC concentration was determined by fluorometry of H
 
2
 
O
 
2
 
 using 3-(4-
hydroxyphenyl) propionic acid (7.5 mM) as a peroxidase donor (Tamaoku
et al., 1982). H
 
2
 
O
 
2
 
 was generated by reaction of LPA with 500 U/ml
monoglyceride lipase (Asahi Chemical Industry Co. Ltd.), 10 U/ml phos-
phocholine phosphodiesterase (GPCP; Asahi Chemical Industry Co. Ltd.),
and 500 U/ml glycero-3-phosphate oxidase (Asahi Chemical Industry Co.
Ltd.) in a buffer containing 50 mM Hepes, 2 mM CaCl
 
2
 
, 0.2% Triton
X-100, and 100 U/ml peroxidase (Toyobo), pH 7.5, in a total volume of
1,500 
 
 
 
l. Fluorescence intensity at excitation at 320 nm/emission at 404
nm was measured by a fluorometer (Hitachi) 5 min after mixing the sam-
ples. LPC concentrations as low as 0.1 nmol could be readily detected.
The assay was linear up to 10 nmol.
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